Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01108393 | Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder | PHASE2 | COMPLETED | 74 | — | — | May 1, 2010 | Apr 1, 2013 | Jul 25, 2024 | 1 | Israel |
Yale-Brown Obsessive Compulsive scale (Y-BOCS) total score. This scale measures the severity of obsessive and compulsive symptoms from baseline to W16.
| Arm | Type | Description |
|---|---|---|
| Agomelatine A | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Agomelatine A | DRUG | Agomelatine 25 mg film-coated tablet Agomelatine 2x25mg film-coated tablet |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Obsessive Compulsive Disorder (OCD) according to Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR), * Y-BOCS total score ≥ 20, * duration of OCD symptoms of at least one year. Exclusion Criteria: * Bipolar disorder, Schizophrenic or Psychotic Disor...